MXPA98010267A - Oxa acids and derivative compounds for the treatment of transtornes of the p - Google Patents

Abstract

The present invention relates to: the use of compounds of the formula (I), which are illustrated below, as active ingredients for the treatment of skin disorders, to compositions containing these compounds, and to methods for the treatment of disorders of the skin by the use of these compounds and compositions (See Formula) wherein R4 is (CR5R6-CR7R9-X1) n, -CR9R1OR11, n is an integer from 1 to 18, R1, R2, R3, R5, R6 , R7, R8, R9, R10 and R11 are independently, hydrogenated or non-hydrogenated substituents, and X, Xi, Y and Z are independently 0, NH

Description

OXA DERIVATIVE ACIDS AND COMPOUNDS FOR THE TREATMENT OF SKIN DISORDERS BACKGROUND OF THE INVENTION I. Field of the Invention The present invention relates to a new class of compounds to be used as active ingredients for the topical treatment of skin disorders, to compositions containing these compounds and methods of treating skin disorders using these compounds and compositions. Compounds of the kind include those of Formula (I): wherein R4 is (CRsRe-CRv s-XiJn-CRgRioRii n is an integer from 1 to 18; Ri, R2, R3, 5 Re ^ R7r Re 9 / Rio and R11 are independently hydrogenated or non-hydrogenated substituents, preferred are non-hydrogenated substituents including alkyl, alkenyl, oxaalkyl, aralkyl and aryl radicals; X, Xi, Y and Z are independently, O, NH or S, with those compounds being preferred wherein X, Xi, Y and Z are each oxygen and REF: 28906 Ri R2 R3 / R5 ß Rs R9 Rio Y R11 are each a hydrogen atom. II. Description of the Prior Art The dermal use of alpha-hydroxy acids having a completely carbon structural base is described in U.S. Patent No. 5,091,171. Cosmetic compositions utilizing 2-hydroxyalkenoic acid are described, for example, in U.S. Patent No. 5,108,751. Such compounds must have an unsubstituted alpha-hydroxy group on a carbon structural base and are intended to be used to impart beneficial effects to the skin. However, the trend is far from the use of such alpha-hydroxy acids, as they need low operating pH ranges, which for most common forms, i.e. glycolic and lactic acids, are known to cause skin irritations. Topical formulations comprising dicarboxylic acids of full carbon structural base, straight chain, have been proposed as replacements for the alpha-hydroxy acids. For example, U.S. Patent Nos. 4,292,326; 4,386,104 and 5,385,943; describe the use of dicarboxylic acids having from 7 to 13 carbon atoms for various indications for the skin. Similarly, US Patent No.

- - No. 4,485,282 states that a dicarboxylic acid compound of 4 to 18 carbon atoms is useful for the treatment of liver disorders. The problem with the use of these dicarboxylic acids is their inherent insolubility in aqueous solutions. Such solutions make up the majority of cosmetic preparation systems. Likewise, dicarboxylic acids having the completely carbon structural base, are solid at room temperature, extremely difficult to work and, if the solution is achieved, the result is an aesthetically unpleasant mixture that is not suitable for cosmetic use. Therefore, there is a need for a compound or classes of compounds that can be used as mild exfoliating active ingredients for the topical treatment of the skin. There is also a need for a mild exfoliating topical composition containing a water-soluble compound, which can be manufactured in the form of an aesthetically acceptable cosmetic or dermatological product. BRIEF DESCRIPTION OF THE INVENTION An object of the present invention is to provide a water-soluble compound or class of compounds that can be manufactured in the form of a mild, aesthetically acceptable exfoliating composition for topical application. Another objective of the present invention is to provide topical compositions with water-soluble compounds, which have multiple benefits for skin care. Another object of the present invention is to provide a new dermatological and cosmetic use for oxa acids. These and other objectives will be evident from the following description. DETAILED DESCRIPTION OF THE INVENTION The basic compound of the present invention is a compound of the following Formula (I): wherein R4 is (CR5R6-CR-7R8-X1) n-CRgRioRn; n is an integer from 1 to 18; Ri, R2, R3 / 5 / Rß / 7 / Rβ R9 / Rio and R ?? they are independently hydrogenated or non-hydrogenated substituents. X, Xi, Y and Z are independently 0, NH or S. Those compounds in which X, Xi, Y and Z - - are oxygen are preferred. Still more preferred are those compounds in which X, x, f, and Z are each oxygen, and Ri, R2, R3, R5, RQ, R7, Rs, Rg Rio and R11 are each a hydrogen atom. Preferred non-hydrogenated substituents include alkyl, alkenyl, oxalkyl, aralkyl and aryl radicals. Examples of non-hydrogenated substituents include methyl, ethyl, propyl, isopropyl, butyl ,. isobutyl, hexyl, heptyl, octyl, nonyl, dodecanyl, ethoxy, ethoxy, propoxy, butoxy, cyclohexenyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, cyclobutyl and cyclohexanyl. Examples of compounds of Formula (I) include 3,6-dioxaheptanoic acid (CHa-0-CH2-CH2-0-CH2-COOH); 7,7-dimethyl-3,6-dioxaheptanoic acid ((CH3) 2CH-0-CH2-CH2-0-CH2-COOH); 3,6-dioxaheptanoic acid ethyl ester (CH3-O-CH2-CH2-0-CH-COOC2H5); 3,6-dioxaheptanoic acid amide (CH3-O-CH2-CH2-O-CH2-CONH2); 3,6-dioxaheptanoic acid dodecylester (CH3-O-CH2-CH2-O-CH2COOC12H25); 2-phenyl-3,6-dioxaheptanoic acid (CH3-0-CH2-CH2-0-CH (Phe) -COOH); 2-benzyl-3,6-dioxaheptanoic acid (CH3-O-CH2-CH2-O-CH (CH2Phe) -COOH); 2-methyl-3,6-dioxaheptanoic acid (CH3-O-CH2-CH2-0-CH (CH3) -COOH); 3-amino-6-oxaheptanoic acid (CH3-O-CH2-CH2-NH-CH2-COOH); 3,6,9-trioxadecanoic acid (CH3-O-CH2-CH2-O-CH2-CH2-O-CH2-COOH); 2-phenyl-3,6,9-trioxadecanoic acid (CH2-0-CH2-CH2-0-CH2-CH2-0-CH (Phe) -COOH); 2-benzyl-3,6,9-trioxadecanoic acid (CH3-O-CH2-CH2-O-CH2-CH2-0-CH (CH2-Phe) -COOH); 2-decyl-3, 6, 9-trioxadecanoic acid (CH3-O-CH2-CH2-O-CH2-CH2-O-CH (C? 0H2?) -COOH); 3, 6, 9, 12-tetraoxatridecanic acid (CH3-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-COOH); 3,6,9,12,15-pentaoxahexadecanoic acid (CH3-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-0-CH2-COOH); 2-methyl-3,6,9-trioxadecanoic acid (CH3-0-CH2-CH2-0-CH2-CH2-0-CH (CH3) -COOH); 10,10-dimethyl-3,6,9-trioxadecanoic acid ((CH3) 2CH-O-CH2-CH2-O-CH2-CH2-O-CH2-COOH) 2-ethyl-3, 6, 9, 12 acid -tetraoxatridecanóico (CH3-O-CH2-CH2-O-CH2-CH2-O-CH2-CH2-O-CH (C2H5) -COOH); 10-phenyl-3,6,9-trioxadecanoic acid (Phe-CH2-0-CH2-CH2-0-CH2-CH2-0-CH2-C00H); 3, 6, 9-trioxadecanoic acid ethyl ester (CH3-O-CH2-CH2-O-CH2-CH2-O-CH2-COOC2H5); 3,6,9-triaminodecanoic acid (CH 3 -NH, CH 2 -CH 2 -NH-CH 2 -CH 2 -NH-CH 2 -COOH); 3, 6, 9, 12-tetraaminotridecanic acid (CH3-NH-CH2-CH2-NH-CH2-CH2-NH-CH2-CH2-NH-CH2-COOH); 9-amino-3,6-dioxadecanoic acid (CH3-NH-CH2-CH2-O-CH2-CH2-O-CH2-COOH); 6, 9-diamino-3-oxadecanoic acid (CH3-NH-CH2-CH2-NH-CH2-CH2-O-CH2-COOH); 3, 6, 9-trithiodecanoic acid (CH3-S-CH2-CH2-S-CH2-CH2-S-CH2-COOH); 9,12-dithio-3,6-dioxatridecanic acid (CH3-S- CH2-CH2-S-CH2-CH2-0-CH2-CH2-0-CH2-COOH); acid monoamide 9-amino-3,6-dioxadecanoic (CH3-NH-CH2-CH2-O-CH2-CH2-O-CH2-CONH2); 3, 6, 9-trioxadecanoic acid monoamide (CH3-0-CH2-CH2-O-CH2-CH2-O-CH2-CONH2); 10,10-dimethyl-3,6,9-trioxadecanoic acid amide ((CH3) 2CH-O-CH2-CH2-O-CH2-CH2-O-CH2-CONH2); 10,10-dimethyl-3,6,9-trioxadecanoic acid ethyl ester ((CH3) 2CH-O-CH2-CH2-O-CH2-CH2-O-CH2-COOC2H5); heptadecaniléster of 10,10-dimethyl-3,6,9-trioxadecanoic acid ((CH3) 2CH-O-CH2-CH2-O-CH2-CH2-O-CH2-COOC1-7H35) and 10,10-dimethyl- 3, 6, 9-trioxadecanoic ((CH3) 2CH-0-CH2-CH2-0-CH2-CH2-0-CH (CH3) -COOH). The compounds of Formula (I) are described as useful intermediates in the preparation of curing agents and hardeners for epoxy resins in US Patent Nos. 5,017,675 and 5,319,004, both assigned to Hoechst AG. Published German Patent Application No. DE-A-2936123, describes the preparation of such epoxy resin intermediate compounds. Such compounds are also commercially available from Hoechst AG. The compounds of Formula (I) can also be prepared from polyamines, polyols and polyols available commercially, by means of routine chemical reactions already known to those skilled in the art, such as amidation, catalytic oxidation, esterification and other known organic chemical synthesis protocols, such as those described in textbooks of organic chemistry, includes March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 3rd ed., John iley Interscience (1985) and Carey et al. , Advanced Organic Chemistry, 3rd ed., Parts A and B, Plenum Press, New York (1990). The oxa acid compounds useful in the topical compositions of the present invention may also be in the form of derivatives that are transformed to an acid form by the action of hydrolytic enzymes in the skin, such as glycosidases, phosphatases, esterases and amidases. Examples of suitable derivatives include esters of the compounds of Formula (I) with aliphatic alcohols, carbohydrates, amides, lactones and anhydrides. As defined herein, all compounds of Formula (I) and derivatives thereof will be collectively referred to as "oxa acids" and / or "oxa compounds" and / or "oxa acid compounds". The term "topical application" refers to the dispersion or direct application on the surface of the skin. The term "topical composition" refers to a composition that is intended to be applied directly or dispersed on the surface of the skin. The term "effective amount" means an amount of a compound or composition sufficient to induce a positive change (e.g., normalization or desquamation) of skin alterations to be treated, such as those attributed to, accompanied by or exacerbated by, abnormal desquamation. The term "physiologically acceptable carrier" or "acceptable topical carrier" refers to drugs, cosmetics, medicaments or inert ingredients that are suitable for use in direct contact with human tissues, without presenting undue toxicity. All percentages refer to percent by weight, based on the total weight of the topical composition. In accordance with the present invention, the oxa compounds are used as active ingredients in topical applications for the treatment of various skin disorders attributed to, accompanied by or exacerbated by, abnormal desquamation. Such disorders include, but are not limited to, dry skin, ichthyosis, palmar and plantar hyperkeratosis, dandruff, chronic simple lichen, Dariers disease, keratosis, - lentigines, age spots, elasmas, battered skin, acne, psoriasis, eczema, pruritus, inflammatory dermatosis, striae due to distension (ie stretch marks), warts and calluses. It was unexpectedly and surprisingly found that the compounds are useful as active agents in topical preparations for the treatment of signs of dermatological aging, both photoaging and intrinsic aging, including wrinkles in the skin such as fine wrinkles in the eye area or rooster "or fine wrinkles around the mouth area, irregular pigmentation, paleness, loss of residence and elasticity of the skin. Oxa compounds and topical compositions containing them are also useful for the treatment of disorders associated with nails, cuticles and hair, such as ingrown hair (buried hair), folliculitis and Pseudo folliculi tis barbae. The compounds of the present also soften the hair and promote the removal of ingrown hairs, making the compounds of Formula (I) useful in shaving compositions. The oxa compounds can be incorporated into the compositions in the form of free acids or in the form of their corresponding salts obtained by neutralization with organic or inorganic bases, such as triethanolamine, arginine, lysine, potassium hydroxide, sodium hydroxide, lithium hydroxide. and ammonium hydroxide. When used in combination with a physiologically acceptable vehicle to form a topical composition, the effective amount of the oxa acid compound may be within the range of about 0.1 to about 95%. Both the effective amount and the frequency of the application will vary within this range based on the particular skin disorder being treated, the age and physical conditions of the person being treated, the severity of the disorder, the duration of the treatment, the nature of other concurrent treatments, the specific compound or compositions being used, the particular vehicle used to deliver the compound or compositions and other similar factors within the knowledge and experience of those skilled in the art. The efficacy of oxa acid compounds in the treatment of skin disorders has been found to be affected by the pH of the composition. In this way, it is believed desirable to maintain the pH of the composition in the acid, pH <range; 7.0 preferably pH < 5.0 more preferably in the pH range between 3.5 and 4.0. The pH of the composition can be adjusted by adding water-soluble salts formed by the action of strong bases (e.g., KOH, NaOH, NHOH) and weak acids (e.g., phosphoric acid, acetic acid, lactic acid, carbonic acid). Examples of such salts include potassium bisphosphate, sodium phosphate, sodium acetate, sodium lactate and the like. Other useful methods for adjusting the pH of topical compositions are known to those skilled in the art. The compositions according to the present invention have clear advantages over the formulations of alpha-hydroxy acids, including a milder action. Formulations containing alpha-hydroxy acids, such as glycolic and lactic acids, can cause substantial discomfort to some individuals and symptoms of severe skin irritation in others? after a facial application. While they are significantly milder for the skin than the glycolic acid formulations, the oxa acids of the present invention are highly effective in normalizing desquamation of the upper stratum corneum. Such normalization is required to alleviate the previously listed skin disorders. The topical compositions of the present invention also have advantages over compositions containing dicarboxylic acids, including better water solubility and superior desquamative or exfoliative activity of the stratum corneum. Oxa acids readily dissolve in water at concentrations of at least 20 to 30% by weight. Therefore, it has been found that oxa acids allow a much wider range of flexibility for the compositions. Dicarboxylic acids with a moderate to long chain length, which have a structural base entirely of carbon and straight chain, are virtually insoluble in water and other aesthetically acceptable vehicles. This severely limits the choice of vehicles to deliver the dicarboxylic acids. The peeling or exfoliating activity of such dicarboxylic acids is also questionable. For example, some tests have shown that formulations containing 5 to 10% dodecanedioic acid do not produce any normalizing effect on the desquamation of the stratum corneum, beyond what the vehicle does on its own. Some specific examples of vehicles suitable for use with the oxa acids include: (1) (a) from about 2 to about 10% by weight of glycerin, (b) from about 1 to about 10% by weight of propylene glycol, (c) ) from about 0.1 to about 2% by weight of hydroxyethylcellulose, (d) from about 0.1 to about 1% by weight of imidazolidinyl urea, and (e) from about 0.01 to about 2% by weight of disodium EDTA; (2) (a) from about 1 to about 10% by weight of glycerin, (b) from about 1 to about 10% by weight of propylene glycol, (c) from about 1 to about 10% by weight of octyl palmitate, (d) from about 1 to about 10% by weight of myristyl myristate, (e) from about 1 to about 6% by weight of cetearyl alcohol / Ceteareth-20, (f) from about 0.5 to about 6% by weight of glyceryl monostearate, (g) from about 0.1 to about 2% by weight of hydroxyethylcellulose, (h) from about 0.1 to about 1% by weight of imidazolidinyl urea, (i) from about 0.05 to about 0.5% by weight of methylparaben and (j) from about 0.01 to about 2% by weight of disodium EDTA; and (3) (a) from about 2 to about 10% by weight of glycerin, (b) from about 1 to about 10% by weight of octyl palmitate, (c) from about 1 to about 10% by weight of myristate of myristyl, (d) from about 1 to about 7% by weight of cetearyl alcohol / Ceteareth-20, (e) from about 1 to about 10% by weight of propylene glycol, (f) from about 1 to about 6% by weight of glyceryl monostearate, (g) from about 0.1 to about 2% by weight of hydroxyethylcellulose, (h) ) from about 0.1 to about 1% by weight of imidazolidinyl urea, (i) from about 0.05 to about 0.5% by weight of methylparaben and (j) from about 0.01 to about 2% by weight of disodium EDTA. The topical compositions of the present invention may be prepared in the form of lotions. A first or more basic lotion comprises: from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acid; and the rest, water. A second lotion has from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acid; from about 0.5 to about 50% by weight of an emollient; from about 0.1 to about 30% by weight of an emulsifier, and the balance water. The second lotion may also contain up to about 10% by weight of a preservative agent; from about 0.1 to about 3% by weight of a fragrance and up to about 5% by weight of a dye or pigment. The topical composition according to the present invention can also be formulated as a cream. A first cream or more basic cream comprises from about 0.1 to about 95% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acid; from about 0.5 to about 50% by weight of an emollient; from about 0.1 to about 6% by weight of a thickener; and the rest water. A second and more preferred cream comprises from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acid; from about 0.5 to about 50% by weight of an emollient; from about 0.1 to about 30 by weight of an emulsifier; from about 0.1 to about 6% by weight of a thickener; and the rest water. Oxa acid can be combined with most conventional emollients, including mineral oil, pertrolate, paraffin, ceresin, ozokerite, microcrystalline wax, perhydrosqualene, dimethylpolysiloxanes, methylphenyl polysiloxanes, silicone / glycol copolymers, triglyceride esters, acetylated monoglycerides, ethoxylated glycerides, alkyl esters of fatty acids, fatty acids and alcohols, lanolin and lanolin derivatives, esters of polyhydric alcohols, sterols, beeswax derivatives, polyhydric alcohols and polyethers, and fatty acid amides. Other suitable emollients can be found in Sagarin, Cosmetics, Science and Technology, 2nd Ed., Vol. 1, pp. 32-43 (1972), the content of which is incorporated herein by reference. The emulsifiers can be cationic, anionic, nonionic, amphoteric or a combination thereof. Nonionic emulsifiers are preferred. Examples of commercially available nonionic emulsifiers are sorbitans, alkoxylated fatty alcohols and alkyl polyglucosides. Anionic emulsifiers can include detergents, alkyl sulfates, onoalkyl and dialkyl phosphates, alkyl sulfonates and acyl isothionates. Other suitable emulsifiers can be found in McCutcheon, Detergents and Emulsifiers, North American Edition, p. 317-324 (1986), the content of which is incorporated herein by reference. Suitable preservatives for use with the compositions according to the present invention include alkanols, especially ethanol and benzyl alcohol, parabens, sorbates, urea-derivatives and isothiazolinones. While such lotions or creams can be prepared using conventional homogenization methods known to those skilled in the art, it is also possible to use a microfluidization process that involves mixing the aqueous phase with the oil phase of such creams and lotions, in a homogenizer high pressure that drastically reduce emulsion particle size to 1/400 the size of those creams and lotions prepared in the application of high pressure. Microfluidization allows the preparation of elegant and stable creams and lotions containing effective amounts of an oxa acid without the use of traditional emulsifiers and surfactants. Topical compositions according to the present invention may also be formulated in the form of an icroemulsion. A first basic microemulsion system comprises from about 0.1 to about 50% by weight, preferably from about 1 to about 30% by weight. weight and more preferably from about 5 to about 20% by weight of the oxa acid; from about 0.5 to about 20% by weight of a hydrocarbon; from about 0.5 to about 20% by weight of an oil; and the rest water. A second, more preferred, microemulsion system comprises from about 1 to about 20% by weight of the oxa acid; from about 0.5 to about 15% by weight of a hydrocarbon; from about 1 to about 15% by weight of an oil; from about 0.1 to about 10% by weight of a fatty alcohol; up to 30% by weight of a nonionic surfactant; and the rest water. The topical compositions of the present invention can be formulated in the form of oil-in-water emulsions or water-in-oil emulsions, gels, lotions, ointments, sticks, sprays, tapes, patches. The compositions in accordance with the present invention may also be in the form of a multi-phase emulsion, such as a water-in-oil-in-water emulsion, such as is described in US Patent No. 4,254,105, which is incorporated herein by reference. present as a reference. The compositions according to the present invention can also be formulated as triple oil-in-water-silicone fluid type emulsions, which are described in US Patent No. 4,960,764, which is incorporated herein by reference. The compositions according to the present invention can also be prepared in the form of liposomal formulations, for example, in accordance with the methods described in Mezei, J. Phar aceut. Pharmacol., - - vol. 34, pp. 473-474 (1982) or a modification thereof. In such compositions, droplets of oxa acid solution can be trapped within liposomal vesicles, where the protection of the liposome is a phospholipid or other suitable lipid (eg, skin lipids). To form a topical composition, the liposomes can be added to any vehicle system of those described above, in accordance, for example, with the modes of preparation, uses and compositions of topical liposomes described in Mezei, Topics in Pharmaceutical ^ iences, Breimer et al. , Eds., Pp. 345-358, Elsevier Science Publishers BV, New York (1985), which is incorporated herein by reference or according to the reverse phase evaporation method described in Szoka et al. , Proc. Nat. Acad. Sciences, vol. 75, pp. 4194-4198 (1978), and Diploses et al. , J. Soc. Cosmetic Chemists, vol. 43, pp. 93-100 (1992), each of which is incorporated herein by reference. The oxa acid solutions can also be entrapped in polymeric vesicles with a shield consisting of a suitable polymeric material, such as gelatin, crosslinked gelatin, polyamide, polyacrylates and the like, to form a vesicle which is subsequently incorporated into the topical composition . The compositions according to the present invention can include an oxa acid compound as the only active ingredient or the oxa acid compound can be used in combination with other cosmetic and pharmaceutical active ingredients and excipients. Other suitable cosmetic and pharmaceutical agents include, but are not limited to, antimycotics, vitamins, sunscreens, retinoids, anti-allergenic agents, depigmentation agents, anti-inflammatory agents, anesthetics, surfactants, humectants, exfoliants, stabilizers, preservatives, antiseptics, thickener lubricants, humectants, chelating agents and penetration enhancers to the skin, as well as emulsifiers, emollients, fragrances and dyes described above. Examples of suitable thickening agents include xanthan gum, brine tolerant xanthan gum, hydroxypropylcellulose, hydroxyethylcellulose, carbopol and acacia gum, Sepigel 305 (available from Seppic Co., France), vee gum or magnesium aluminum silicate. In topical compositions, the oxa acids are also compatible with and their utility can be improved by, humectants, such as urea, PCA, amino acids, certain polyols and other compounds with hygroscopic properties. Topical compositions containing from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acid, in combination with a keratolytic agent, such as salicylic acid and benzoyl peroxide and skin lightening agents such as benzoquinone of kojic acid, licorice derivatives, ascorbic acid and its derivatives (e.g., magnesium ascorbyl phosphate) and glyceretinic acid and its derivatives. Approximately 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acid can be used to prepare a topical formulation in combination with sunscreens organic and inorganic, such as titanium dioxide, zinc oxide, benzylidenecamphor, anthranilates, butylmethoxydibenzoylmethanes, naphtholsulfonates and cinnamic acid derivatives. Of these, butylmethoxydibenzoylmethane and cinnamic acid derivatives are preferred. The topical compositions according to the present invention also contain from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acids together with (i) retinoids, such as retinol, retinoic acid, retinyl palmitate, retinyl propionate, retinyl acetate, isotretinoin, as well as synthetic retinoid-like compounds; (ii) hormonal compounds such as estriol, estradiol, estrone or conjugated estrogens; (iii) alpha-hydroxy acids or polyhydroxy alpha-hydroxy acids such as glycolic acid, lactic acid, aric acid, gluconic acid and other carboxylic acids and their monomeric, polymeric, cyclic or acyclic derivatives; (iv) alpha-keto acids such as pyruvic acid, 2-oxopropanoic acid, 2-oxobutanoic acid, 2-oxpentanoic acid and the like. Also from about 0.1 to about 90% by weight, preferably from about L to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acids can be used to obtain additional benefits in topical formulations that you contain one or more of the following: (i) vitamins, including, for example, enzymatic cofactors such as vitamin B6, vitamin B12, vitamin D3, 1, 25-dihydroxy-vitamin D3, vitamin Bl, vitamin B2, vitamin K, vitamin E , tocotrienols and their derivatives, nicotinic acid and its esters, pantothenic acid and its esters, panthenol, folic acid and its derivatives, choline, carnitine and substances without a formal vitamin status or "pseudovitamins" such as vitamin F or cis, cis- linoleic acid, vitamin M or pteroylglutamic acid, vitamins BIO and Bll, sesame seed factor, termitin, penicin, insectin, hypomycin and mycoin, vitamin L or anthranilic acid, itamine L2 or adeniltiomethylpentose, myoinositol or cis-1, 2, 3, 5-trans-4,6-cyclohexanehexol and its esters, especially phytic acid, laetrile or 1-mandelonitril-beta-glucuronic acid, amygdalin, vitamin B15 or pagamic acid , vitamin B13 or orotic acid, vitamin H3 or procaine hydrochloride, vitamin U or methylsulfonium salts of methionine and pyrroloquinoline quinone; (ii) antifungal agents including, for example, clotrimazole, ketocoalanzole, miconazole, naftifine, tolnaftate, amphotericin B, nystatin, 5-fluorocytosine, griseofulvin, haloprogin, of which tolnaftate, haloprogin and miconazole are most preferred; (iii) self-tanning agents including, for example, dihydroxyacetone and lausone, of which dihydroxyacetone is preferred; (iv) agents against mycobacteria such as erythromycin, tetracycline and related compounds, especially toxicicin and metacycline, cephalosporins, penicillins, macrolides, peptide compounds such as - - novobiocin, vancomycin, oleandomycin, paromomycin, leucomycin, ampomycin with macrolide molecules, quinolone derivatives and other compounds that interfere with the synthesis of the bacterial cell wall, the membrane function of RNA metabolism, the synthesis of pyrimidine purines and proteins, respiration or phosphorylation; (v) topical analgesics such as lidocaine, benzocaine, butacaine, tetracaine, clove oil and eugenol, of which benzocaine and lidocaine are most preferred; (vi) lipid compounds essential for skin barrier function, including for example, ceramides, essential fatty oils and their esters, especially glycerides,? -hydroxy fatty acids and their esters derived with alkanols through the carboxylic hydroxyl or with other acids fatty acids in the omega-hydroxyl of which the latter type is preferred, with phospholipids, cholesterol and their esters, such as cholesteryl hemisuccinate and cholesteryl phosphate, of which cholesterol phosphate and essential fatty acids are most preferred , phytosterols, cholestanol and their derivatives. The lipid compounds can be added to a topical composition either in the form of simple molecular entities, or else, in the form of a complex mixture of lipids derived from a synthesis of animal or plant products; (vii) antiallergenic agents and antihistamines Hl and / or H2, such as diphenylhydramine, clemizole, antazoline, tenaldine, phenyltoloxamine citrate, tricyclic antiallergens such as ketotifen, dithiaden and thiadene 3-thienylsulfide, H2 receptor blockers, especially burimamide, methylamide and cimetidiene, chromic acid and its salts; (viii) oxa acids can be used with topical anti-inflammatory agents that can reduce inflammation. These anti-inflammatory agents are used in concentrations of approximately 0.025 to 10% by weight, preferably 0.5 to 1% by weight, the anti-inflammatory concentration being adjusted upwards or downwards, depending on the potency of the agents used. Examples of spheroid anti-inflammatories that can be used with oxa acids include hydrocortisone, hydroxyvitriacillone, alpha-methyl-dexamethasone, dexamethasone phosphate, beclamethasone dipropionate, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, prednisolone and mixtures thereof, the more preferred are prednisolone and hydrocortisone; and (ix) anti-inflammatories - - non-spheroids such as those described in Rainsford, Anti-Inflammatory and Anti-Rheumatic Drugs, Vols. I-III, CRC Press, Boca Raton, Florida (1985), and specific examples of non-spheroidal anti-inflammatories (NSAIDs) include, for example, oxicamos (e.g., piroxicam, isoxicam), phenamic acid derivatives, meclofenamic acid derivatives (for example, sodium meclofenamate), flufenamic acid derivatives, mefenamic acid derivatives, propionic acid esters such as ibuprofen, naproxen, benoxaprofen, flubiprofen, ketoprofen, suprofen, of which ibuprofen is the most preferred; pyrazolidinediones, of which phenylbutazone is most preferred; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, of which indomethacin is the "most preferred; derivatives of salicylic acid, such as, for example, aspirin, disalacid and benorilate, of which aspirin and disalacid are most preferred. The compositions according to the present invention can also include safe anti-inflammatory products of natural origin, which have been shown to possess anti-inflammatory activity, such as aloe vera extracts, Rubis genus extracts (Rubia Cordifolia), extracts of the genus Commiphom (Commiphora Mukul). ), willow bark, flowers of archaea, flowers of arnica, roots of plants of the genus Symphytum, seeds of fenugreek and the like, known to those skilled in the art. The topical compositions according to the present invention may contain from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acids, in combination with antioxidants having hydroxyphenolic functions such as gallic acid derivatives (e.g., propyl gallate), bio-flavonoids (e.g., quercetin, rutin, daidzein, gentistein), ferric acid derivatives, (e.g., ethyl ferrulate) , sodium ferrulate), 6-hydroxy-2,5,7-tetramethylchroman-2-carboxylic acid. The compositions may also contain effective concentrations of water-soluble antioxidants such as uric acid, reductic acid, tannic acid, rosmarinic acid and catechins. A co-formulation with from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acids with inhibitors of the enzyme nitric oxide is also beneficial. synthetase, which reduce redness of the skin, vasodilation and inflammatory reactions, especially in response to electromagnetic and ionizing radiation or the action of chemical or biochemically aggressive compounds. Nitric oxide synthetase enzyme inhibitors can be added in concentrations of 0.05 to 10% by weight, preferably 1 to 3% by weight and are selected from the group consisting of guanidine derivatives, especially monoaminoguadine and methylguanidine, derivatives of L-arginine, cc especially N-nitro-L-arginine and its esters, N -monomethyl-L-arginine, 2-iminopiperidines and other 2-iminoazaheterocyclics. Other possible antioxidants that the composition may contain are those having one or more thiol (-SH) functions, either in reduced form or in non-reduced form, such as glutathione, lipoic acid, thioglycolic acid and other sulfhydryl compounds. The levels of sulfhydryl antioxidants should not exceed 0.5% by weight for cosmetic uses of the composition, but may be higher for pharmaceutical uses, as necessary considering the efficacy. The composition may also include inorganic antioxidants such as sulfites, bisulfites, metabisulfites or other inorganic salts and acids containing sulfur in an oxidation state of +4. The preferred level of inorganic antioxidants containing sulfur is from about 0.01 to about 0.5% by weight, with a level from about 0.1 to about 0.4% by weight being most preferred. The compositions according to the present invention can also include from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acids, co-formulated with about 0.025 to about 5% by weight, with 0.5 to 2% by weight being preferred and 0.5 to 1% by weight more preferred, of compounds known to be spin traps. of electrons such as nitrones, N-tert-butylnitrona and a- (4-pyridyl-1-oxide) -N-tert-butylnitrona or other compounds known to form free radicals with average lifetimes greater than one minute. It can also be used from about 0.1 to about 90% by weight, preferably from about 1 to about 50% by weight and more preferably from about 5 to about 20% by weight of the oxa acids, in compositions containing insect repellents such as aliphatic, cyclic or aromatic amides, citronella oil, terpineol , cineol, margosa oil and terephthalic acid and their esters. Other suitable insect repellents can be found in Technical Bulletin No. 1549 of the United States Department of Agriculture or in their Agricultural Handbooks Nos. 69, 340 and 461. Topical compositions containing oxa acids in accordance with present invention, may also contain skin refreshing compounds such as, for example, menthol, menthylglycerol, asymmetric carbonates, thiocarbonates and urethanes, N-substituted carboxamides, ureas or phosphine oxides such as those described in J. Cosmet. Chem., Vol. 29, p. 185 (1978), menthyl lactate and menthone glycerin acetal. The general activity and softness for the skin of the topical compositions of the present invention can also be increased by neutralization at a pH of 3.5 to 7.0, preferably from 3.7 to 5.6, with one or more amphoteric and pseudoamphoteric compounds such as glycine. , alanine, valine, serine, thionin, methionine, leucine, asparagine, histidine, glutamic acid, glutamine, usina, cystine, cysteine, tryptophan, serine, phenylalanine, citrulline, creatine, proline, 3- or 4-hydroxyproline, 5-hydroxylysine , ornithine and its derivatives, 3-aminopropanoic acid and other aminocarboxylic acids, canavanine, channeline, homoarginine, taurine, aminoaldonic and aminosugar acids, aminouronic acid, aminoaldárico acid, desacetylated hyaluronic acid, hyaluronic acid, chondrosine, desulfated heparin, neuroamínico or sialic acid , methionisulphone, glycylglycine, chondroitin, D, L-sphingosine, sphingomyelin, ophidine, glucagon, homocarnosine, phosphatidyl rina, cocoanfoglicin, phosphatidylethanolamine, cysteinsulfinic acid, glutathione, amphoteric inorganic oxides, polyamidoamines, dendrimers based on polyamidoamines, sodium hydroxymethylglycinate and polyethyleneamine. The usefulness and softness of the topical compositions of the present invention can also be increased by certain chelating agents incorporated in the composition at concentrations from about 0.01 to about 25% by weight, preferably from about 0.5 to about 10% by weight and more preferably from about 1 to about 5% by weight. Examples of suitable chelating agents include those having a high affinity for zinc, calcium, magnesium, iron and / or copper ions, such as ethylenediaminetetraacetic acid, (ethyldioxy) -diethylenedinitrile-tetraacetic acid, salicylaldoxime, quinolinol, diaminocyclohexane-tetraacetic acid , diethylenetriamine pentaacetic acid, dimethylglyoxime, benzoinoxime, triethylenetetraamine, deferoxamine or mixtures thereof. The present invention also includes methods by which these compounds can be used to treat the aforementioned skin disorders. Such methods include the topical application of an effective amount of one or more of the compounds of Formula (I) to the affected skin areas, usually once or twice a day. Such methods also include the topical application of a composition containing an effective amount of one or more compounds of the Formula (I) in a physiologically acceptable carrier to the affected skin areas, usually once or twice a day. Methods according to the present invention include topical application of the compounds of Formula (I) in concentrations up to 100%, when such compounds are in the liquid state at room temperature (eg, 3, 6, 9-trioxa acid). ? rndecanodióico) and when oxa compounds are used, for example, to flake the skin or soften the hair. The following Examples are illustrative of the present invention and are not intended to limit it. EXAMPLES The compositions of the present invention are generally prepared in the form of lotions, creams or gels for topical application. EXAMPLE 1 Preparation of Oxa Acid Compositions for Application - -Topical In a suitable container, glycerin, propylene glycol, Na2AEDT and 3, 6, 9-trioxadecanoic acid are mixed. Ammonium hydroxide is added to the vessel in increments, to adjust the pH to the desired range. Then, this phase with the adjusted pH is heated to 77-79 ° C (170-175 ° F). Subsequently, hydroxyethylcellulose is added with stirring until the mixture is uniform, to conclude phase A. For the lotion and cream, phase B is added to a second suitable container, combined and heated to 77-79 ° C (170 -175 ° F). Subsequently, phase B is added to phase A by mixing enough, once again it is heated to 77-79 ° C (170-L75 ° F). Afterwards, the batch is cooled to 49 ° C (120 ° F). Phase C is added to the batch and mixed until the mixture is uniform. Phase GEL LOTION CREAM (A) water c.b.p. c.b.p. c.b.p. glycerin 5.00 3.00 5.00 propylene glycol 3.00 3.00 3.00 disodium EDTA 0.10 0.10 0.10 3, 6, 9-trioxadecanoic acid 10.00 10.00 10.00 hydroxyethylcellulose 0.50 0.30 0.500 ammonium hydroxide at pH to pH (30%) 3.7-3.9 3.7-3.9 3.7-3.9 Phase GEL CREAM LOTION (B) octyl palmitate-3. 00 5. 00 myristyl myristate - 3. 00 5.00 glycemic monostearate-1 .50 3. 00 rite cetearyl alcohol and - 3.00 5.00 Ceteareth-20 methylparaben - 0.20 0.20 (C) imidazolidinyl urea 0.30 0.30 0.30 All numbers are expressed as percentages with respect to the total weight of the composition, except for the pH ranges and the quantities c.b.p. to balance with water.

Those skilled in the art will readily realize that other possible vehicles other than lotions, creams or gels provide the benefits of the present disclosure. Microscopic normalization of the desquamation of the stratum corneum or macroscopic exfoliation of the epidermis are required activities to alleviate the skin disorders that are intended with the compounds and oxa acid compositions of the present invention. The following Examples demonstrate, inter alia, the desquamative activity of the upper stratum corneum provided by the oxa acid compositions of the present invention.

EXAMPLE 2 Cream for Hyperpigmented Stains This Example illustrates a cream that can be prepared and used to reduce the appearance of spots by hyperpigmentation in the skin of the hands. % by weight isopropyl myristate 3.0 polyethylene glycol monostearate (1000) 5.0 palmitic acid 10.0 3, 6, 9-trioxadecanoic acid 10.0 glycerin 3.0 polyethylene glycol monostearate (300) 5.0 methylparaben 0.2 magnesium ascorbyl phosphate 2.0 water 60.0 perfume and dye up to 100.0 triethanolamine up pH 4.0 All numbers are expressed as percentages with respect to the total weight "of the composition, except for reference to pH.

EXAMPLE 3 Cream for Dry Skin, Ichthyosis and Hyperkeratosis This Example illustrates a silicone cream that can be prepared and used for the treatment of dry skin, ichthyosis and hyperkeratosis, in accordance with the present invention. %in weigh Phase A laurylmethicone 2.0 copolyol mineral oil 1.0 lanolin 1.5 sunflower or soybean oil 10.0 cyclomethicone 6.0 soluble rosemary oil extract 2.0 Phase B sodium iodide 2.0 3, 6, 9-trioxadecanoic acid 9.0 3-amino-6-oxaheptanoic acid 1.0 sodium hydroxymethyl glycinate 0.5 demineralized water up to 100.0 sodium biphosphate up to pH 3.8 All numbers are expressed as percentages based on the total weight of the composition, except for reference to pH.

EXAMPLE 4 Silicone Gel This Example illustrates a water gel composition in silicone. %in weigh Phase A dimeticonsl 10.0 dimethicone copolyol 10.0 cyclomethicone 5.0 Phase B 3,6-dioxaheptanoic acid 8.0 glycerin 20.0 demineralized water up to 100.0 triethanolamine up to pH 4.0 All numbers are expressed as a percentage based on the total weight of the composition, except for reference to pH.

- - EXAMPLE 5 Cream for Acne, Skin Imperfections and Bleeding Stains This Example illustrates a face cream that can be used for the treatment of acne, skin imperfections and age spots. %in weigh Phase A oleic acid 1.0 stearic acid 17.0 polyoxyethylene (propylene glycol monostearate 20) 10.0 retinol 0.1 Phase B glycerin 5.0 2-pyrrolidone-5-carboxylic acid 5.0 3, 6, 9-trioxadecanoic acid 7.5 3,6-dioxaheptanoic acid amide 2.5 lactic acid 3.0 demineralized water up to 100.0 ammonium hydroxide up to pH 4.2 All the numbers are expressed as a percentage with respect to the total weight of the composition, except for the retention of the pH.

Various modifications and alterations to the present invention can be devised based on the revision of the present description. These changes and additions are intended to be within the scope and spirit of the present invention, as defined by the following claims.

- - It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention. Having described the invention as an antecedent, what is contained in the following is claimed as property.

Claims (52)

1. CLAIMS 1. A topical composition characterized in that it comprises a suitable topical vehicle and compound of Formula (I): • R * wherein R4 is (CR5R6-CR7RS-X1) n-CR9R? or R? i / n is an integer from 1 to 18; R <r> R <2>, R <3>, R <5>, R <s>, R <s>, R <s>, R <9>, Rio and R-1: are independently, hydrogenated or non-hydrogenated substituents; and X, X :, Y and Z are independently O, NH or S.
2. 2. The composition according to claim 1, characterized in that the compound of the Formula (I) comprises from about 0.1 to about 95% by weight of the composition.
3. 3. The composition according to claim 2, characterized in that the compound of the Formula (I) comprises from about 1 to about 50% by weight of the composition.
4. 4. The composition according to claim 3, characterized in that the compound of the Formula (I) comprises from about 5 to about 20% by weight of the composition. The composition according to claim 1, characterized in that n is an integer from 2 to 12. The composition according to claim 1, characterized in that it also comprises a mixture of at least two different compounds of the Formula ( I). The composition according to claim 1, characterized in that the non-hydrogenated substituents of the compound are selected from the group consisting of alkyl, alkenyl, oxaalkyl, aralkyl and aryl radicals. The composition according to claim 7, characterized in that the non-hydrogenated substituents are selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, hexyl, heptyl, octyl, nonyl, dodecanyl, ethoxy, ethoxy radicals , propoxy, butoxy, cyclohexenyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, cyclobutyl and cyclohexanyl. 9. The composition according to claim 1, characterized in that Ri, R2, Rs, Rs Rd / R-, RA, R ?, Rio and Rn are each a hydrogen atom. 10. The composition according to claim 1, characterized in that X, Xi, Y and Z are each an oxygen atom. 11. The composition according to claim 1, characterized in that X, Xi, Y and Z are each an amino group. 12. The composition according to claim 1, characterized by X, Xi, Y and Z are each a sulfur atom. The composition according to claim 1, characterized in that the compound is selected from the group consisting of 3,6-dioxaheptanoic acid; 7, 7-dimethyl-3,6-dioxaheptanoic acid; 3,6-dioxaheptanoic acid ethyl ester; 3,6-dioxaheptanoic acid amide; 3,6-dioxaheptanoic acid dodecylester; 2-phenyl-3,6-dioxaheptanoic acid; 2-benzyl-3,6-dioxaheptanoic acid; 2-methyl-3,6-dioxaheptanoic acid; 3-amino-6-oxaheptanoic acid; 3, 6, 9-trioxadecanoic acid; 2-phenyl-3,6,9-trioxadecanoic acid; 2-benzyl-3,6,9-trioxadecanoic acid; 2-decyl-3, 6, 9-trioxadecanoic acid; 3, 6, 9, 12-tetraoxatridecanic acid; 3, 6, 9, 12, 15-pentaoxahexadecanoic acid; 2-methyl-3,6,9-trioxadecanoic acid; 10,10-dimethyl-3,6,9-trioxadecanoic acid; 2-ethyl-3, 6, 9, 12-tetraoxatridecanic acid; 10-phenyl-3,6,9-trioxadecanoic acid; 3,6,9-trioxadecanoic acid ethyl ester; 3, 6, 9-triaminodecanoic acid; 3, 6, 9, 12-tetraaminotridecanic acid; 9-amino-3,6-dioxadecanoic acid; 6, 9-diamino-3-oxadecanoic acid; 3, 6, 9-trithiodecanoic acid; 9, 12-dithio-3,6-dioxatridecanic acid; 9-amino-3,6-dioxadecanoic acid monoamide; 3, 6, 9-trioxadecanoic acid monoamide; 10,10-dimethyl-3,6,9-trioxadecanoic acid amide; 10,10-dimethyl-3,6,9-trioxadecanoic acid ethyl ester; heptadecanilyester dt - 10,10-dimethyl-3,6,9-trioxadecanoic acid and 10,10-dimethyl-3,6,9-trioxadecanoic acid and mixtures thereof. The composition according to claim 1, characterized in that the vehicle is selected from the group consisting of lotion, cream and gel. 15. The composition according to claim 1, characterized in that it also comprises at least one active principle that is selected from the group consisting of antimycotics, vitamins, sunscreens, retinoids, antiallergenic agents, depigmentation agents, anti-inflammatory agents, anesthetics, surfactants , humectants, exfoliants, emulsifiers, stabilizers, preservatives, antiseptics, emollients, thickeners, lubricants, humectants, chelating agents, fragrances, dyes and penetration enhancers to the skin. 16. The composition according to claim 1, characterized in that the composition has a pH less than 7.0. 17. The composition according to claim 16, characterized in that the pH is from about 3.5 to about 7.0 18. The composition according to claim 17, characterized in that the pH is from about 3.5 to about 7.0 19. The composition in accordance with claim 2, characterized in that the composition comprises from about 1 to about 50% by weight of the compound of the Formula (I) and has a pH of less than 7.0. The composition according to claim 16, characterized in that the topical carrier comprises from 0.1 to about 95% by weight of the compound of the Formula (I); from 0.5 to about 50% by weight of an emollient and from about 0.1 to about 30% by weight of an emulsifier. The composition according to claim 20, characterized in that the compound is selected from the group consisting of 3,6-dioxaheptanoic acid, 3,6,9-trioxadecanoic acid, 3, 6, 9, 12-tetraoxatridecanic acid and 3,6,9,12,15-pentaoxahexadecanoic; wherein the emollient is selected from the group consisting of mineral oil, pertrolate, paraffin, ceresin, ozokerite, microcrystalline wax, perhydrosqualene, dimethyl polysiloxanes, methylphenyl polysiloxanes, silicone / glycol copolymers, triglyceride esters, acetylated monoglycerides, ethoxylated glycerides, esters alkyl of fatty acids, fatty acids and alcohols, lanolin and lanolin derivatives, esters of polyhydric alcohols, sterols, beeswax derivatives, polyhydric alcohols and polyethers, and fatty acid amides; and wherein the emulsifier is selected from the group consisting of sorbitans, alkoxylated fatty alcohols, alkyl polyglycosides, detergents, alkyl sulfates, monoalkyl and dialkyl phosphates, alkyl sulfonates and acyl isotynates. The composition according to claim 2, characterized in that the composition is in a form that is selected from the group consisting of an oil-in-water emulsion, a water-in-oil emulsion, a water-in-oil in water emulsion and a water-in-oil emulsion. oil in water-liquid silicone. 23. The composition according to claim 14, characterized in that the topical carrier comprises an ingredient selected from the group consisting of ammonium hydroxide, cetearyl alcohol / Ceteareth-20, EDTA, glycerin, glyceryl monostearate, hydroxyethylcellulose, imidazolidinyl. urea, methylparaben, myristyl myristate, octyl palmitate and propylene glycol, and mixtures thereof. The composition according to claim 14, characterized in that it comprises from about 0.1 to about 20% by weight of 3,6,9-trioxadecanoic acid and a carrier. The composition according to claim 22, characterized in that the carrier comprises: (a) from about 2 about 10% by weight of glycerin; and (b) from about 1 to about 10% by weight of propylene glycol; and said composition has a pH of about 7.0 or less. 26. The composition according to claim 25, characterized in that the vehicle further comprises from about 0.1 to about 2% by weight of hydroxyethylcellulose. The composition according to claim 26, characterized in that the carrier further comprises: from about 0.1 to about 1% by weight of imidazolidinyl urea and from about 0.01 to about 2% by weight of disodium EDTA. The composition according to claim 24, characterized in that the vehicle comprises: (a) from about 1 to about 10% by weight of glycerin; (b) from about 1 to about 10% by weight of propylene glycol; (c) from about 1 to about 10% by weight of octyl palmitate; (d) from about 1 to about 10% by weight of myristyl myristate; (e) from about 1 to about 6% by weight cetearyl alcohol / Ceteareth-20; and (f) from about 0.5 to about 6% by weight of glyceryl monostearate; and said composition has a pH of about 7.0 or less. 29. The composition according to claim 28, characterized in that the vehicle further comprises from about 0.1 to about 2% by weight of hydroxyethylcellulose. The composition according to claim 29, characterized in that the vehicle further comprises: from about 0.1 to about 1% by weight of imidazolidinyl urea; from about 0.05 to about 0.5% by weight of methylparaben and from about 0.01 to about 2% by weight of disodium EDTA. The composition according to claim 24, characterized in that the vehicle comprises: (a) from about 2 to about 10% by weight of glycerin; (b) from about 1 to about 10% by weight of octyl palmitate; (c) from about 1 to about 10% by weight of myristyl myristate; (d) from about 1 to about 7% by weight cetearyl alcohol / Ceteareth-20; (e) from about 1 to about 10% by weight of propylene glycol; and (f) from about 1 to about 6% by weight of glyceryl monostearate; and said composition has a pH of about 7.0 or less. 32. The composition according to claim 31, characterized in that the vehicle further comprises from about 0.1 to about 2% by weight of hydroxyethylcellulose. The composition according to claim 32, characterized in that the vehicle further comprises: from about 0.1 to about 1% by weight of imidazolidinyl urea; from about 0.05 to about 0.5% by weight of methylparaben and from about 0.01 to about 2% by weight of disodium EDTA. 34. A method for the cosmetic treatment of skin disorders caused by, accompanied by or exacerbated by, abnormal desquamation, characterized in that it comprises applying to the skin an effective amount of a compound of Formula (I) wherein R4 is (CR5R6-CR7R8-X1) n-CR9R?; R ??, n is an integer from 1 to "18; Rl R2, R3, R5, Rβ, R ?, Rβ, R9 / Rio and R11 are independently hydrogenated or non-hydrogenated substituents, and X, Xx, Y and Z are independently O, NH or S. 35. The method according to claim 34, characterized in that the compound is combined with a suitable topical carrier. 36. The method according to claim 34, further comprising applying to the skin an effective amount of a mixture of two or more different compounds of the Formula (I). according to claim 35, characterized in that the compound of the formula (I) comprises from about 0.1 to about 95% by weight of the composition 38. The method according to claim 37, characterized in that the compound of the formula (I) ) comprises from about 1 to about 50% by weight of the composition. 39. The method according to claim 37, characterized in that n is an integer from 2 to 12. 40. The method according to claim 34, characterized in that the non-hydrogenated substituents of the compound are selected from the group consisting of radicals. alkyl, alkenyl, oxaalkyl, aralkyl and aryl. 41. The method according to claim 40, characterized in that the non-hydrogenated substituents of the compound are selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, hexyl, heptyl, octyl, nonyl, dodecanyl, methoxy radicals , ethoxy, propoxy, butoxy, cyclohexenyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, cyclobutyl and cyclohexanyl. 42. The method according to claim 34, characterized in that Rx, R2 / R3, R5, R6, R7, Re, Rs, Rio and Rn are each a hydrogen atom. 43. The method according to claim 34, characterized in that X, Xx, Y and Z are each an oxygen atom. 44. The method according to claim 34, characterized in that X, Xx, Y and Z are each an amino group. 45. The method according to claim 34, characterized in that X, Xi, Y and Z are each a sulfur atom. 46. The method according to claim 34, characterized in that the compound is selected from the group consisting of 3,6-dioxaheptanoic acid; 7, 7-dimethyl-3,6-dioxaheptanoic acid; 3,6-dioxaheptanoic acid ethyl ester; 3,6-dioxaheptanoic acid amide; 3,6-dioxaheptanoic acid dodecylester; 2-phenyl-3,6-dioxaheptanoic acid; 2-benzyl-3,6-dioxaheptanoic acid; 2-methyl-3,6-dioxaheptanoic acid; 3-amino-6-oxaheptanoic acid; 3, 6, 9-trioxadecanoic acid; 2-phenyl-3,6,9-trioxadecanoic acid; 2-benzyl-3,6,9-trioxadecanoic acid; 2-decyl-3, 6, 9-trioxadecanoic acid; 3, 6, 9, 12-tetraoxatridecanic acid; 3, 6, 9, 12, 15-pentaoxahexadecanoic acid; 2-methyl-3,6,9-trioxadecanoic acid; 10,10-dimethyl-3,6,9-trioxadecanoic acid; 2-ethyl-3, 6, 9, 12-tetraoxatridecanic acid; 10-pentyl-3,6,9-trioxadecanoic acid; 3,6,9-trioxadecanoic acid ethyl ester; 3, 6, 9-triaminodecanoic acid; 3, 6, 9, 12-tetraaminotridecanic acid; 9-amino-3,6-dioxadecanoic acid; 6, 9-diamino-3-oxadecanoic acid; 3, 6, 9-tritiodecanoic acid; 9, 12-dithio-3,6-dioxatridecanic acid; 9-amino-3,6-dioxadecanoic acid monoamide; 3, 6, 9-trioxadecanoic acid monoamide; 10,10-dimethyl-3,6,9-trioxadecanoic acid amide; 10,10-dimethyl-3,6,9-trioxadecanoic acid ethyl ester; heptadecaniléster of 10,10-dimethyl-3,6,9-trioxadecanoic acid and 10,10-dimethyl-3,6,9-trioxadecanoic acid and mixtures thereof. 47. The method according to claim 46, characterized in that the compound is 3,6,9-trioxadecanoic acid. 48. The method according to claim 34, characterized in that the skin disorders are selected from the group consisting of skin - - dry, ichthyosis, palmar and plantar hyperkeratosis, dandruff, chronic lichen simplex, Dariers disease, keratosis, lentigines, age spots, melasmas, battered skin, acne, psoriasis, eczema, pruritus, inflammatory dermatosis, stretch marks for distension, warts and calluses , signs of dermatological aging, wrinkled skin, fine wrinkles around the mouth area, irregular pigmentation, paleness, loss of residence and elasticity of the skin and disorders associated with nails, cuticles and hair. 49. The method according to claim 35, characterized in that the composition further comprises at least one active principle that is selected from the group consisting of antimycotics, vitamins, sunscreens, retinoids, anti-allergenic agents, depigmentation agents, anti-inflammatory agents, anesthetics. , surfactants, humectants, exfoliants, emulsifiers, stabilizers, preservatives, antiseptics, emollients, thickeners, lubricants, humectants, chelating agents, fragrances, dyes and penetration enhancers to the skin. 50. A method of exfoliating the skin characterized in that it comprises applying to the skin a compound of the Formula (I): - - wherein R4 is (CR5R6-CR7R8-X?) r-CR9R? 0R, n is an integer from 1 to 18; R1, R2, R3, R5 Re, Ri, Rs, R RID and Rii are independently, hydrogenated or non-hydrogenated substituents; and X, Xi, Y and Z are independently O, NH or S. 51. A method for softening the hair, characterized in that it comprises applying to the hair a compound of the Formula (I): wherein R4 is (CR5R6-CR7R8-X?) n-CR3R? 0 ??, n is an integer from 1 to 18; Rx, R2, R3, R5 Re / R7 / Rβ / R? / Rio Y R:? they are independently, hydrogenated or non-hydrogenated substituents; and X, Xi, Y and Z are independently O, NH or S. 52. The composition according to claim 1, characterized in that the compound of the Formula (I) contains at least one terminal acid group.